key: cord-1022429-0f9yp8rg
authors: Ang, Lin; Lee, Hye Won; Kim, Anna; Lee, Myeong Soo
title: Herbal Medicine for the management of COVID-19 during the medical observation period: A review of guidelines
date: 2020-07-01
journal: Integr Med Res
DOI: 10.1016/j.imr.2020.100465
sha: 04f13a9e97514aa5fcb95733f48452b2ae3120dc
doc_id: 1022429
cord_uid: 0f9yp8rg

BACKGROUND: Medical observation period is a period of 14 days after any exposure to coronavirus disease 2019 (COVID-19) occurred. This review aimed to summarize and analyze the herbs and herbal formulae recommended by available guidelines. METHODS: A total of 14 sources were searched for potential guidelines that provide herbal medicine treatment for the medical observation period of COVID-19. We summarized and analyzed the recommended herbal formulae and performed a network analysis to identify the relationship between herbs. RESULTS: We found 9 guidelines that provide herbal formula for medical observation based on clinical manifestation. There are 12 herbal formulae with a total of 53 herbs recommended by the guidelines. The result of our network analysis showed that the herb Citri Reticulatae Pericarpium (Chen Pi) strongly paired with the herb Glycyrrhizae Radix et Rhizoma (Gan Cao). CONCLUSION: This review briefly summarized the usage of herbal medicine for the medical observation period of COVID-19 and may serve as a reference for future studies. More research is needed in the future to provide evidence on the usage of herbal medicine in various phases of COVID-10.

The recent emergence of a novel coronavirus has caused a pandemic and sickened more than 2.5 million people in at least 177 countries. 1, 2 This novel strain of coronavirus which caused coronavirus disease 2019 (COVID-19) also belonged to the same family of viruses that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) in the past. 3 The infection of COVID-19 can result in acute respiratory illness and present common symptoms such as fever, cough, and fatigue. 4 According to reports from World Health J o u r n a l P r e -p r o o f

Organizations, evidence has shown that there are three routes for the transmission of COVID- 19 : symptomatic transmission, pre-symptomatic transmission, and asymptomatic transmission. 5 A recent publication also showed that the actual intervals of transmission are shorter than the incubation period which suggests that pre-symptomatic transmission is more substantial than expected. 6 Hence, it is hard to predict or estimate the potential spread of COVID-19. As the understanding of COVID-19 remains limited, active monitoring, surveillance, and control of the disease are crucial for public health. 7 Medical observation period is defined as a period of 14 days after any exposure of COVID-19 occurred and is set based on the incubation time from virus exposure to illness onset. 7, 8 Individuals who are put under medical observation are usually those who required monitoring and restriction of movements (i.e., home quarantine and quarantine stations). They are required to complete the 14 days of medical observation before they are given medical clearance.

To date, many guidelines related to herbal medicine have been issued for the prevention and treatment of COVID-19. 9, 10 Recent clinical evidence also showed the therapeutic effectiveness of traditional medicine in treating different stages of COVID-19. [11] [12] [13] In this review, we aimed to summarize and analyze the herbal formulae recommended for use during the medical observation period of COVID-19.

The following data sources were searched up to June 2, 2020 for eligible guidelines: 

This review only focused on the treatment of modalities for COVID-19 during the medical observation period. All guidelines that provide treatment measures related to herbal medicine in the form of oral ingested herbal formula or single herbs were included. Herbal medicines in the form of patent medicine, herbal injections, herbal patches, and herbal fumigation were excluded. Guidelines that only provide preventive measures or treatment measures for confirmed cases of COVID-19 were also excluded.

Data from each included guideline were extracted using a predefined data extraction table. The 

In this review, we systematically summarized and analyzed the herbal formulae recommended for use during the medical observation period of COVID-19. Medical observation period of 14 days not only includes individuals that are exposed to the virus but also those that recovered from the diseases, where both circumstances required active monitoring. However, the individuals that required to be under medical observation period might slightly differ from country to country according to their severity distributions. 16 Additionally, a prior study on the distribution patterns of herbs used for respiratory disease treatment using data mining methods also reported that Glycyrrhizae Radix et Rhizoma was often grouped with Citri Reticulatae Pericarpium. 17 Studies also showed that the herb Citri Reticulatae Pericarpium has anti-inflammatory and anti-asthmatic properties which may relieve fever, soothe cough and dyspnea, stimulate appetite, as well as enhance the immune system. 18, 19 Particularly, the recommended dosage range for the herb Glycyrrhizae Radix et Rhizoma for the analysis of this study as we intended to identify the relationships between herbs using network analysis. As the clinical symptoms presented during the medical observation period are mainly mild, patent medicines such as over-the-counter herbal medicines are often prescribed. Another limitation of this study is the lack of information. Additional information is not available in the relevant guidelines even though the medical observation period includes different groups of individuals (i.e. exposed to the virus, recovered from the disease, confirmed without signs of acute respiratory infection, symptomatic, or non-symptomatic) that may require different therapeutic principles. Besides, current researches on COVID-19 primarily focused on the potential treatment measures in various disease stages. There are very few studies that mention the medication used during medical observation period in general. Hence, we are unable to obtain much information or evidence to conduct a more comprehensive review.

In conclusion, this review provided an insight into the potential role of herbal medicine in regulating COVID-19 during the medical observation period. Although we are unable to provide a firm recommendation, this study serves as a reference for future studies. It is necessary to define the usage of herbal medicine in various phases of COVID-19, including before and aftercare. 

The authors declare no conflict of interest.

This study is supported by the Korea Institute of Oriental Medicine (KSN2013210).

No ethics committee approval was required as no human or animal research was conducted.

Data will be made available upon request. 

Fatigue + fever

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

A novel coronavirus outbreak of global health concern

Coronavirus disease 2019 (COVID-19) Situation Report -73

Transmission interval estimates suggest pre-symptomatic spread of

The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application

Insight into 2019 novel coronavirus -an updated intrim review and lessons from SARS-CoV and MERS-CoV

Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines

Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs

COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease

Clinical effects of integrated traditional Chinese and western medicine on COVID-19: a systematic review

Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective

Analysis of the Medication Rule of Glycyrrhiza uralensiscontaining Antitussive Prescriptions Based on 2015 Edition of Chinese Pharmacopoeia (Part Ⅰ)

Essentials of Chinese materia medica and medical formulas: new century traditional Chinese medicine

Study of the distribution patterns of the constituent herbs in classical Chinese medicine prescriptions treating respiratory disease by data mining methods

Identification of anti-asthmatic compounds in Pericarpium citri reticulatae and evaluation of their synergistic effects

Citri Reticulatae Pericarpium (Chen Pi)(Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine

Study on in vitro anti-inflammatory activity of total flavonoids from Glycyrrhizae Radix et Rhizoma (Gan Cao) and its ingredients

In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds

Traditional Chinese herbal medicine as a source of molecules with antiviral activity

The Pharmacological Activities of Licorice

Analysis on herbal medicines utilized for treatment of COVID-19

Gui Zhi) 12g, Atractylodis Rhizoma (Cang Zhu) 12g, Acori Tatarinowii Rhizoma (Shi Chang Pu) 12g, Agastachis Herba (Huo Xiang) 12g, Crataegi Fructus (Shan Zha) 15g, Citri Reticulatae Pericarpium (Chen Pi) 9g, Pinelliae Rhizoma (Ban Xia) 9g, Poria Sclerotium (Fu Ling) 12g, Puerariae Radix (Ge Gen) 12g, Scutellariae Radix (Huang Qin) 12g, Lonicerae Flos (Jin Yin Hua) 9g, Zingiberis Rhizoma Recens (Sheng Jiang) 30g, Glycyrrhizae Radix et Rhizoma

Huang Qi) 20g, Codonopsis Radix (Dang Shen) 15g, Atractylodis Macrocephalae Rhizoma (Bai Zhu) 15g, Poria Sclerotium (Fu Ling) 15g, Citri Reticulatae Pericarpium (Chen Pi) 10g, Bupleuri Radix (Chai Hu) 10g, Lonicerae Flos (Jin Yin Hua) 15g, Saposhnikoviae Radix (Fang Feng) 10g, Angelicae Sinensis Radix (Dang Gui) 15g, Paeoniae Radix (Chi Shao) 15g, Chuanxiong Rhizoma (Chuan Xiong) 10g, Armeniacae Semen Amarum (Ku Xing Ren) 10g, Ophiopogonis Radix (Mai Dong) 15g, Glycyrrhizae Radix et Rhizoma

Notopterygii Rhizoma seu Radix (Qiang Huo) 10g, Atractylodis Rhizoma (Cang Zhu) 10g, Perillae Folium (Su Ye ) 10g, Armeniacae Semen Amarum (Ku Xing Ren) 10g, Eupatorii Herba (Pei Lan) 10g, Agastachis Herba (Huo Xiang) 10g, Citri Reticulatae Pericarpium (Chen Pi) 6g, Peucedani Radix (Qian Hu) 10g, Bupleuri Radix (Chai Hu) 10g, Menthae Herba (Bo He) 6g, Platycodonis Radix (Jie Geng) 6g, Glycyrrhizae Radix et Rhizoma

Jing Jie) 15g, Saposhnikoviae Radix (Fang Feng) 15g, Ephedrae Herba (Ma Huang) 10g, Angelicae Dahuricae Radix (Bai Zhi) 10g, Notopterygii Rhizoma seu Radix (Qiang Huo) 15g, Bupleuri Radix (Chai Hu) 15g, Peucedani Radix (Qian Hu) 10g, Platycodonis Radix (Jie Geng) 10g, Aurantii Fructus (Zhi Qiao) 10g, Chuanxiong Rhizoma (Chuan Xiong) 15g, Agastachis Herba (Huo Xiang) 10g, Atractylodis Rhizoma (Cang Zhu) 15g, Zingiberis Rhizoma Recens

Lian Qiao) 30g, Imperatae Rhizoma (Bai Mao Gen) 30g, Platycodonis Radix (Jie Geng)10 g, Phragmitis Rhizoma (Lu Gen) 30g, Glycyrrhizae Radix et Rhizoma

Chai Hu) 9g, Scutellariae Radix (Huang Qin) 9g, Pinelliae Rhizoma (Ban Xia) 9g, Crassirhizomae Rhizoma (Guan Zhong) 9g, Lonicerae Flos (Jin Yin Hua) 15g, Forsythiae Fructus (Lian Qiao) 15g, Pseudostellariae Radix (Tai Zi Shen) 10g, Astragali Radix (Huang Qi) 15g, Saposhnikoviae Radix (Fang Feng) 9g, Atractylodis Macrocephalae Rhizoma (Bai Zhu) 9g, Glycyrrhizae Radix et Rhizoma

Huang Qi) 9g, Glehniae Radix (Bei Sha Shen) 9g, Anemarrhenae Rhizoma (Zhi Mu) 9g, Tropaeoli Herba (Han Jin Lian) 5g, Forsythiae Fructus (Lian Qiao) 9g, Atractylodis Rhizoma (Cang Zhu) 9g

Korea No clear symptoms Forsythiae Fructus (Lian Qiao) 8g, Lonicerae Flos (Jin Yin Hua) 8g, Schizonepetae Spica (Jing Jie) 8g, Saposhnikoviae Radix (Fang Feng) 8g, Notopterygii Rhizoma seu Radix (Qiang Huo) 8g, Araliae Continentalis Radix (Du Huo) 8g, Bupleuri Radix (Chai Hu) 8g, Peucedani Radix (Qian Hu) 8g, Cnidii Rhizoma (Chuan Xiong) 8g, Aurantii Fructus (Zhi Qiao) 8g, Platycodonis Radix (Jie Geng) 8g, Poria Sclerotium (Fu Ling) 8g, Glycyrrhizae Radix et Rhizoma (Gan Cao) 16g, Menthae Herba (Bo He) 2g, Zingiberis Rhizoma Recens (Sheng Jiang) 28g, Atractylodis Rhizoma (Cang Zhu) 16g, Magnoliae Cortex (Hou Po) 8g, Citri Unshius Pericarpium (Chen Pi) 8g, Agastachis Herba (Huo Xiang) 8g, Pinelliae Rhizoma (Ban Xia) 8g, Zizyphi Fructus

Gan Cao) 16g, Angelicae Gigantis Radix (Dang Gui) 4g, Citri Unshius Pericarpium (Chen Pi) 4g, Cimicifugae Rhizoma (Sheng Ma) 3g